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Abstract
Background: Several reproductive and hormonal factors
are known to be associated with ovarian cancer risk in
the general population, including parity and oral
contraceptive (OC) use. However, their effect on ovarian
cancer risk for BRCA1 and BRCA2 mutation carriers has
only been investigated in a small number of studies.
Methods: We used data on 2,281 BRCA1 carriers and
1,038 BRCA2 carriers from the International BRCA1/2
Carrier Cohort Study to evaluate the effect of repro-
ductive and hormonal factors on ovarian cancer risk for
mutation carriers. Data were analyzed within a weight-
ed Cox proportional hazards framework.
Results: There were no significant differences in the
risk of ovarian cancer between parous and nulliparous
carriers. For parous BRCA1 mutation carriers, the risk
of ovarian cancer was reduced with each additional
full-term pregnancy (P trend = 0.002). BRCA1 carriers
who had ever used OC were at a significantly reduced
risk of developing ovarian cancer (hazard ratio, 0.52;
95% confidence intervals, 0.37-0.73; P = 0.0002) and
increasing duration of OC use was associated with a
reduced ovarian cancer risk (P trend = 0.0004). The
protective effect of OC use for BRCA1 mutation carriers
seemed to be greater among more recent users. Tubal
ligation was associated with a reduced risk of ovarian
cancer for BRCA1 carriers (hazard ratio, 0.42; 95%
confidence intervals, 0.22-0.80; P = 0.008). The number
of ovarian cancer cases in BRCA2 mutation carriers was
too small to draw definitive conclusions.
Conclusions: The results provide further confirmation that
OCuse, numberof full-termpregnancies, and tubal ligation
are associated with ovarian cancer risk in BRCA1 carriers
to a similar relative extent as in the general population.
(Cancer Epidemiol Biomarkers Prev 2009;18(2):601–10)
Introduction
Pathogenic mutations in BRCA1 and BRCA2 confer high
risks of breast and ovarian cancer. The estimated ovarian
cancer risk by age 70 years has been reported to be 16%
to 66% in BRCA1 mutation carriers and 11% to 27% in
BRCA2 mutation carriers (1-8). Other than age and
family history, the strongest known risk factors for
ovarian cancer are parity, in which risk decreases with
increasing number of pregnancies, and oral contraceptive
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(OC) use, in which risk decreases with increasing
duration of use (9-11). Breast-feeding and tubal ligation
have also been reported to be associated with a risk of
reduced ovarian cancer (10-13). However, the effect of
these and other risk factors on ovarian cancer risk in
BRCA1 and BRCA2 mutation carriers has only been
investigated in a few studies (14-20), most of which have
included relatively few carriers. As a result, the relative
risk estimates are imprecise. Most studies have concen-
trated on the effect of OC use because of its potential to
be used as chemoprevention for ovarian cancer risk in
mutation carriers. The majority of the studies have found
that OC use is associated with a reduced risk of ovarian
cancer in mutation carriers (14-16, 18), although Modan
et al. (17) reported no association. Parity has also been
examined in several studies, and has been found to
decrease the risk of ovarian cancer in BRCA1 mutation
carriers alone, or in BRCA1 and BRCA2 carriers
combined (14, 15, 17). In the largest study to date, parous
BRCA1 mutation carriers were found be at a reduced risk
of ovarian cancer (16). Surprisingly, however, parity was
associated with an increased risk of ovarian cancer in
BRCA2 mutation carriers (16). The associations with
other factors are yet to be established in mutation
carriers.
In the general population, several of the risk factors for
ovarian cancer are also risk factors for breast cancer, but
the magnitude and direction of the effect may differ. In
particular, OC use is protective for ovarian cancer but
confers an increased risk of breast cancer (9, 21). There is
some evidence that these associations may also be
present in BRCA1 and BRCA2 carriers (16, 22). As the
lifetime risks of both breast and ovarian cancer are high
in BRCA1 and, to a lesser extent, BRCA2 carriers, it is
important to establish whether OC use increases or
decreases the overall risk of cancer in carriers. To answer
such questions, it is important to obtain precise estimates
of the effects of these risk factors using large, well-
designed studies.
We have previously used data from the International
BRCA1 and BRCA2 Carrier Cohort Study (IBCCS) to
investigate the effect of reproductive and hormonal
factors as well as the effect of radiation exposure on
breast cancer risk in mutation carriers (22-25). The IBCCS
cohort is a large series of BRCA1 and BRCA2 mutation
carriers that is mostly independent of those used in
previously published studies which investigated the
ovarian cancer risk factors described above. In this
report, the IBCCS data set was used to evaluate the
effect of reproductive and hormonal factors on ovarian
cancer risk in BRCA1 and BRCA2 mutation carriers.
Materials and Methods
Study Group. IBCCS was initiated in 1997 at the IARC
to prospectively estimate risks of breast, ovarian, and
other cancers in BRCA1 and BRCA2 carriers and to assess
lifestyle and genetic factors that may modify the cancer
risks in such individuals. One of the aims of this project
is to evaluate the role of reproductive and hormonal
factors as well as intervention therapies as potential
modifiers of cancer risks in BRCA1 and BRCA2 mutation
carriers. Details of the design and rationale of the study
have been described elsewhere (26). Subjects are eligible
to participate in IBCCS if they are carriers of pathogenic
mutations in either BRCA1 or BRCA2 , >18 years old,
capable of giving informed consent, and have been
counseled as to their mutation status.
The present study is a retrospective analysis of 3,319
female mutation carriers (2,281 BRCA1 and 1,038 BRCA2)
recruited during the period 1997 to 2005. All mutation
carriers were European with the exception of 139 subjects
from Quebec. Out of the 3,319 participants, 2,410
were from large ongoing national studies of BRCA1/2
mutation carriers in the United Kingdom and Eire
(EMBRACE), the Netherlands (GEO-HEBON), and
France (GENEPSO). A standardized questionnaire was
administered either by mail, in-person interview at the
time of genetic counseling, or through telephone inter-
view, depending on study center. The questionnaire
requested detailed information on known or suspected
risk factors for ovarian and breast cancer, including the
timing of menarche and menopause, a detailed pregnan-
cy history, OC and hormone replacement therapy (HRT)
use, and surgical interventions (oophorectomy, hysterec-
tomy, tubal ligation, and mastectomy). The research
protocol was approved by the relevant ethics committees
and all participants provided written informed consent.
Statistical Methods. The aim of the present study was
to evaluate the effect of various factors on the risk of
developing ovarian cancer for BRCA1 and BRCA2
mutation carriers. The data were analyzed within a Cox
proportional hazards framework. The majority of the
mutation carriers in IBCCS come from families with
multiple cases of breast and ovarian cancer seen in
clinical genetic centers. Thus, the selection of mutation
carriers in our study is nonrandom with respect to
disease status. In addition, affected and unaffected
carriers are likely to be sampled with different probabil-
ities at different ages because genetic testing is primarily
targeted at affected individuals diagnosed at an early
age. Therefore, the carriers in our study do not represent
a true cohort. We have previously shown that under
these conditions, standard Cox regression analysis leads
to biased estimates of the rate ratios. To correct for this
bias, we developed a weighted cohort approach (27).
Briefly, this method involves assigning different weights
to cancer cases and unaffected individuals such that the
observed incidence rates are consistent with established
incidence rates in mutation carriers. For the current
analyses, we have extended this approach to take into
account the potential oversampling with respect to
both breast and ovarian cancer cases simultaneously
(Appendix 1). The BRCA1 and BRCA2 weights were
derived assuming the age-specific incidence rate esti-
mates reported in Antoniou et al. (1).
In our main analyses, individuals were censored at the
first of the following events: ovarian cancer diagnosis
(253), breast cancer diagnosis (1,641), other cancer
diagnosis (51), bilateral prophylactic oophorectomy
(186), or at interview (1,188). Subjects censored at ovarian
cancer diagnosis were considered affected (cases).
Weights for the weighted Cox regression analysis were
derived assuming this censoring process. To increase the
number of ovarian cancer cases used in the analysis,
additional analyses were done in which we did not
censor at a breast cancer diagnosis but instead having
had a breast cancer was included as a time-dependent
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Table 1. IBCCS cohort characteristics
Characteristic Total BRCA1 mutation carriers* BRCA2 mutation carriers*
Unaffected Breast cancer Ovarian
cancer
Unaffected Breast cancer Ovarian
cancer
Number of carriers (n) 3,319 970 1,110 201 455 531 52
Mean age at interview (SD) 46.5 (12.1) 40.2 (11.5) 48.9 (10.6) 54.7 (9.6) 42.9 (11.3) 51.4 (10.8) 62.4 (10.0)
Mean age at censoring (SD) 41.2 (10.0) 39.0 (10.5) 40.0 (8.7) 48.4 (8.4) 41.8 (10.6) 43.1 (8.8) 54.4 (9.9)
Person-years of follow-up 137,632 37,806 44,984 9,833 19,028 23,128 2,853
Cohort (%)
<1940 381 (11.5) 43 (4.4) 140 (12.6) 50 (24.9) 31 (6.8) 90 (17.0) 27 (51.9)
z1940-1949 669 (20.2) 117 (12.1) 274 (24.7) 63 (31.3) 55 (12.1) 144 (27.1) 16 (30.8)
z1950-1959 985 (29.7) 214 (22.1) 397 (35.8) 70 (34.8) 123 (27.0) 174 (32.8) 7 (13.5)
z1960 1,284 (38.7) 596 (61.4) 299 (26.9) 18 (9.0) 246 (54.1) 123 (23.2) 2 (3.9)
Country group
c
(%)
Group 1 913 (27.5) 366 (37.7) 356 (32.1) 51 (25.4) 72 (15.8) 60 (11.3) 8 (15.4)
Group 2 234 (7.1) 87 (9.0) 69 (6.2) 24 (11.9) 28 (6.2) 24 (4.5) 2 (3.9)
Group 3 1,130 (34.0) 259 (26.7) 375 (33.8) 78 (38.8) 159 (34.9) 235 (44.3) 24 (46.2)
Group 4 1,042 (31.4) 258 (26.6) 310 (27.9) 48 (23.9) 196 (43.1) 212 (39.9) 18 (34.6)
Number of full-term pregnancies
b
(%)
0 693 (20.9) 275 (28.4) 211 (19.0) 15 (7.5) 107 (23.5) 82 (15.4) 3 (5.8)
1 542 (16.3) 132 (13.6) 222 (20.0) 31 (15.4) 70 (15.4) 78 (14.7) 9 (17.3)
2 1,211 (36.5) 337 (34.7) 412 (37.1) 82 (40.8) 156 (34.3) 207 (39.0) 17 (32.7)
3 593 (17.9) 152 (15.7) 181 (16.3) 51 (25.4) 90 (19.8) 108 (20.3) 11 (21.2)
z4 259 (7.8) 67 (6.9) 80 (7.2) 21 (10.5) 27 (5.9) 52 (9.8) 12 (23.1)
Missing 21 (0.6) 7 (0.7) 4 (0.4) 1 (0.5) 5 (1.1) 4 (0.8) 0 (0)
Age at first full-term pregnancy (%)
<20 299 (11.5) 74 (10.8) 113 (12.6) 21 (11.4) 37 (10.8) 45 (10.1) 9 (18.4)
20-24 1,050 (40.3) 260 (37.8) 393 (43.9) 82 (44.3) 118 (34.4) 175 (39.3) 22 (44.9)
25-29 886 (34.0) 256 (37.2) 287 (32.1) 53 (28.7) 119 (34.7) 160 (36.0) 11 (22.5)
z30 370 (14.2) 98 (14.2) 102 (11.4) 29 (15.7) 69 (20.1) 65 (14.6) 7 (14.3)
Breast-feeding among parous (%)
Never 815 (31.3) 185 (26.9) 283 (31.6) 58 (31.4) 121 (35.3) 152 (34.2) 16 (32.7)
Ever 1,790 (68.7) 503 (73.1) 612 (68.4) 127 (68.7) 222 (64.7) 293 (65.8) 33 (67.4)
Breast-feeding duration among parous, months (%)
0 815 (31.3) 185 (26.9) 283 (31.6) 58 (31.4) 121 (35.3) 152 (34.2) 16 (32.7)
1-5 774 (29.7) 201 (29.2) 280 (31.3) 47 (25.4) 100 (29.2) 131 (29.4) 15 (30.6)
6-12 589 (22.6) 176 (25.6) 198 (22.1) 44 (23.8) 63 (18.4) 97 (21.8) 11 (22.5)
13-24 283 (10.9) 87 (12.7) 94 (10.5) 16 (8.7) 41 (12.0) 40 (9.0) 5 (10.2)
>24 106 (4.1) 32 (4.7) 28 (3.1) 11 (6.0) 14 (4.1) 20 (4.5) 1 (2.0)
Unknown 38 (1.5) 7 (1.0) 12 (1.3) 9 (4.9) 4 (1.2) 5 (1.1) 1 (2.0)
Age at menarche (%)
<12 561 (16.9) 156 (16.1) 203 (18.3) 24 (11.9) 78 (17.1) 90 (16.9) 10 (19.2)
12-14 2,187 (65.9) 648 (66.8) 719 (64.8) 146 (72.6) 305 (67.0) 337 (63.5) 32 (61.5)
z15 531 (16.0) 153 (15.8) 175 (15.8) 26 (12.9) 68 (15.0) 99 (18.6) 10 (19.2)
Missing 40 (1.2) 13 (1.3) 13 (1.2) 5 (2.5) 4 (0.9) 5 (0.9) 0
OC use
Never 766 (23.1) 160 (16.5) 269 (24.2) 92 (45.8) 72 (15.8) 144 (27.1) 28 (53.9)
Ever 2,415 (72.8) 767 (79.1) 790 (71.2) 98 (48.8) 363 (79.8) 375 (70.6) 22 (42.3)
Missing 138 (4.2) 43 (4.4) 51 (4.6) 11 (5.5) 19 (4.2) 12 (2.3) 2 (3.9)
OC use duration, years (%)
Never 766 (23.1) 160 (16.5) 269 (24.0) 92 (45.8) 73 (15.8) 144 (27.1) 28 (53.9)
>0-1 339 (10.2) 75 (7.7) 108 (9.7) 36 (17.9) 48 (10.6) 68 (12.8) 4 (7.7)
>1-3 338 (10.2) 97 (10.0) 109 (9.8) 18 (9.0) 52 (11.4) 55 (10.4) 7 (13.5)
>3-5 289 (8.7) 93 (9.6) 81 (7.3) 8 (4.0) 54 (11.9) 55 (10.4) 2 (3.9)
>5 1,248 (37.6) 412 (42.5) 437 (39.4) 33 (16.4) 176 (38.7) 183 (34.5) 7 (13.5)
Missing 339 (10.2) 137 (14.1) 106 (9.6) 14 (7.0) 52 (11.4) 26 (4.9) 4 (7.7)
HRT use (%)
Never 2,502 (75.4) 655 (67.5) 901 (81.2) 164 (81.6) 323 (71.0) 427 (80.4) 32 (61.5)
Ever 270 (8.1) 69 (7.1) 66 (5.9) 27 (13.4) 47 (10.3) 46 (8.7) 15 (28.9)
Missing 547 (16.5) 246 (25.4) 143 (12.9) 10 (5.0) 85 (18.7) 58 (10.9) 5 (9.6)
Tubal ligation (%)
Never 2,649 (79.8) 774 (79.8) 880 (79.3) 166 (82.6) 364 (80.0) 420 (79.1) 45 (86.5)
Yes 423 (12.7) 113 (11.6) 124 (11.2) 18 (9.0) 77 (16.9) 86 (16.2) 5 (9.6)
Missing 247 (7.4) 83 (8.6) 106 (9.55) 17 (8.5) 14 (3.1) 25 (4.7) 2 (3.8)
Hysterectomy (%)
Never 3,178 (95.6) 944 (97.3) 1,051 (94.7) 192 (95.5) 429 (94.3) 510 (96.1) 48 (92.3)
Yes 115 (3.5) 19 (2.0) 47 (4.2) 7 (3.5) 23 (5.1) 16 (3.0) 3 (5.8)
Missing 30 (0.9) 7 (0.7) 12 (1.1) 2 (1.0) 3 (0.7) 5 (0.9) 1 (1.9)
*Censoring based on the first cancer diagnosis.
cGroup 1: Austria, Belgium, Germany, Netherlands, Hungary, Poland; group 2: Denmark, Sweden; group 3: France, Italy, Quebec, Spain; group 4: United
Kingdom and Eire.
bNumber of live births and stillbirths by the age at censoring.
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Table 2. Ovarian cancer HR estimates in BRCA1 and BRCA2 carriers combined and separately, under weighted cohort analysis
Factor All HR (95% CI) P BRCA1 HR (95% CI) P BRCA2 HR (95% CI) P
Unaffected Ovarian cancer Unaffected Ovarian cancer Unaffected Ovarian cancer
Parity*
Nulliparous 675 18 1.00 486 15 1.00 189 3 1.00
Parous 2,371 234 1.42 (0.79-2.57) 0.24 1,583 185 1.40 (0.75-2.61) 0.30 788 49 1.93 (0.51-7.39) 0.34
Full-term pregnancies (reference group: nulliparous)*
0 675 18 1.00 486 15 1.00 0.02 347 12 1.00
1 502 40 2.33 (1.23-4.43) 0.01 354 31 2.24 (1.13-4.43)
2 1,112 99 1.35 (0.74-2.48) 0.33 749 82 1.35 (0.71-2.56) 0.36 363 17 0.56 (0.19-1.64) 0.29
3 531 62 1.28 (0.65-2.52) 0.48 333 51 1.30 (0.63-2.66) 0.48 198 11 0.40 (0.11-1.47) 0.17
z4 226 33 0.76 (0.65-1.66) 0.49 147 21 0.67 (0.28-1.62) 0.38 79 12 0.54 (0.16-1.86) 0.33
Full-term pregnancies*
0 675 18 0.43 (0.23-0.81) 0.01 486 15 0.45 (0.23-0.88) 0.02 347 12 1.00
1 502 40 1.00 354 31 1.00
2 1,112 99 0.58 (0.38-0.89) 0.01 749 82 0.60 (0.38-0.96) 0.03 363 17 0.56 (0.19-1.64) 0.29
3 531 62 0.55 (0.34-0.89) 0.02 333 51 0.58 (0.35-0.97) 0.04 198 11 0.40 (0.11-1.47) 0.17
z4 226 33 0.33 (0.17-0.63) 0.001 147 21 0.30 (0.14-0.64) 0.002 79 12 0.54 (0.16-1.86) 0.33
Age at full-term pregnancy*
<20 269 30 1.00 187 21 1.00 82 9 1.00
20-24 946 104 1.11 (0.65-1.89) 0.71 653 82 1.21 (0.66-2.20) 0.53 293 22 0.57 (0.18-1.81) 0.34
25-29 822 64 0.84 (0.47-1.49) 0.55 543 53 0.95 (0.51-1.79) 0.88 279 11 0.28 (0.08-1.02) 0.05
z30 334 36 1.50 (0.81-2.78) 0.19 200 29 1.60 (0.82-3.14) 0.17 134 7 1.04 (0.25-4.33) 0.96
Nulliparous 675 18 0.74 (0.35-1.56) 0.43 486 15 0.82 (0.37-1.84) 0.63 189 3 0.29 (0.06-1.45) 0.13
Breast-feeding*
Never 741 74 1.00 468 58 1.00 273 16 1.00
Ever 1,630 160 0.88 (0.62-1.26) 0.50 1,115 127 0.90 (0.61-1.32) 0.59 515 33 0.72 (0.27-1.91) 0.51
Nulliparous 675 18 0.70 (0.38-1.29) 0.25 486 15 0.72 (0.38-1.39) 0.33 189 3 0.42 (0.09-1.91) 0.26
Breast-feeding duration (mo)*
Never 741 74 1.00 468 58 1.00 273 16 1.00
1-5 712 62 0.79 (0.52-1.20) 0.27 481 47 0.81 (0.52-1.26) 0.35 231 15 0.59 (0.19-1.89) 0.38
6-12 534 55 1.06 (0.67-1.68) 0.82 374 44 1.05 (0.64-1.73) 0.84 160 11 1.07 (0.32-3.60) 0.92
13-24 262 21 0.55 (0.29-1.03) 0.06 181 16 0.52 (0.26-1.04) 0.07 115 6 0.64 (0.14-2.88) 0.56
>24 94 12 0.71 (0.29-1.70) 0.44 60 11 0.71 (0.28-1.80) 0.47
Nulliparous 675 18 0.70 (0.38-1.28) 0.25 486 15 0.72 (0.38-1.38) 0.33 189 3 0.42 (0.09-1.93) 0.27
Age at menarche
c
<12 527 34 1.00 359 24 1.00 168 10 1.00
12-14 2,009 178 0.92 (0.58-1.46) 0.74 1,367 146 0.94 (0.57-1.57) 0.83 642 32 0.91 (0.33-2.51) 0.86
z15 495 36 0.65 (0.36-1.19) 0.17 328 26 0.66 (0.34-1.27) 0.21 167 10 0.86 (0.23-3.24) 0.82
OC use
b
Never 646 120 1.00 429 92 1.00 217 28 1.00
Ever 2,295 120 0.55 (0.40-0.76) 0.0003 1,557 98 0.52 (0.37-0.73) 0.0002 738 22 1.04 (0.42-2.54) 0.94
OC duration of use (y)
b
Never 646 120 1.00 429 92 1.00 217 28 1.00
>0-1 299 40 1.04 (0.66-1.62) 0.88 183 36 1.03 (0.64-1.65) 0.91
332 13 1.33 (0.52-3.39) 0.56>1-3 313 25 0.60 (0.35-1.03) 0.06 206 18 0.51 (0.28-0.93) 0.03
>3-5 279 10 0.41 (0.19-0.87) 0.02 170 8 0.40 (0.17-0.91) 0.03
>5 1,208 40 0.35 (0.22-0.55) 5  106 849 33 0.34 (0.21-0.54) 6  106 359 7 0.59 (0.16-2.24) 0.44
OC start age
b
Never 646 120 1.72 (1.05-2.82) 0.03 429 92 1.75 (1.05-2.90) 0.03 217 28 1.25 (0.31-5.08) 0.76
(Continued on the following page )
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Table 2. Ovarian cancer HR estimates in BRCA1 and BRCA2 carriers combined and separately, under weighted cohort analysis (Cont’d)
Factor All HR (95% CI) P BRCA1 HR (95% CI) P BRCA2 HR (95% CI) P
Unaffected Ovarian cancer Unaffected Ovarian cancer Unaffected Ovarian cancer
<20 1,181 36 1.00 844 32 1.00 590 10 1.00
20-24 707 41 0.88 (0.51-1.50) 0.63 454 35 0.86 (0.49-1.50) 0.59
z25 407 43 0.96 (0.53-1.73) 0.89 259 31 0.87 (0.46-1.65) 0.67 148 12 1.46 (0.35-6.01) 0.60
OC: Calendar year at start
b
Never 646 120 2.18 (1.50-3.18) 5  105 429 92 2.40 (1.58-3.61) 3  105 217 28 0.98 (0.40-2.41) 0.40
<1975 790 73 1.00 527 57 1.00 263 16 1.00
z1975 1,505 47 1.63 (0.95-2.81) 0.08 1,030 41 1.74 (0.98-3.10) 0.06 475 6 1.16 (0.27-5.01) 0.84
OC: Time since last use
b
Never 646 120 1.00 429 92 1.00 217 28 1.00
Current or <10 y 1,077 24 0.29 (0.18-0.48) 1  106 790 20 0.28 (0.17-0.48) 2  106 287 4 0.38 (0.10-1.45) 0.16
z10 y 1,218 96 0.85 (0.59-1.21) 0.36 767 78 0.80 (0.55-1.18) 0.26 451 18 1.76 (0.63-4.94) 0.63
HRT use
c
Never 2,306 196 1.00 1,556 164 1.00 750 32 1.00
Ever 228 42 0.89 (0.53-1.47) 0.64 135 27 0.89 (0.48-1.63) 0.70 93 15 1.06 (0.45-2.51) 0.90
HRT by duration (y)
c
Never 2,306 196 1.00 1,556 164 1.00 750 32 1.00
>0-5 137 21 1.18 (0.63-2.21) 0.60 87 18 1.30 (0.65-2.60) 0.45 93 15 1.06 (0.45-2.51) 0.90
>5-10 51 11 0.74 (0.29-1.89) 0.53 48 9 0.51 (0.19-1.39) 0.19
>10 40 10 0.47 (0.19-1.20) 0.12
Tubal ligation
c
Never 2,438 211 1.00 1,654 166 1.00 784 45 1.00
Yes 400 23 0.43 (0.24-0.75) 0.003 237 18 0.42 (0.22-0.80) 0.008 163 5 0.47 (0.18-1.21) 0.12
Age at tubal ligation
c
Never 2,438 211 3.40 (1.45-7.99) 0.005 1,654 166 4.60 (1.51-13.96) 0.007 784 45 1.00
V35 232 9 1.00 138 5 1.00 163 5 0.47 (0.18-1.21) 0.12
>35 168 14 2.00 (0.68-5.86) 0.21 99 13 3.14 (0.87-11.28) 0.08
Hysterectomy
c
Never 2,934 240 1.00 1,955 192 1.00 939 48 1.00
Yes 105 10 0.59 (0.22-1.57) 0.29 66 7 0.68 (0.22-2.12) 0.51 39 3 0.35 (0.08-1.58) 0.17
*Adjusted for duration of OC use.
cAdjusted for duration of OC use and number of full-term pregnancies.
bAdjusted for full-term pregnancy.
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covariate. In this analysis, all subjects were allocated
disease-specific weights as above. These analyses should
be valid provided that the ascertainment depends on the
first, but not a subsequent, cancer diagnosis.
With the exception of age at menarche, all the risk
factors were analyzed as time-dependent covariates.
Women for whom the age at which the covariates
changed were unknown were included in an unknown
category for the relevant analyses. Pregnancy-related
variables were considered up to 1 year prior to the
censoring age, in line with previous IBCCS analyses (23).
All analyses were stratified by birth cohort (<1940, 1940-
1949, 1950-1959, 1960+) and country grouping (group 1:
Austria, Belgium, Germany, Netherlands, Hungary, and
Poland; group 2: Denmark, Sweden; group 3: France,
Italy, Quebec, Spain; group 4: United Kingdom and Eire).
Stratification by country was done to reflect potential
differences in ovarian cancer incidence and risk factor
prevalence. Each of the large studies (United Kingdom,
France, and the Netherlands) were assigned to separate
groups. The combined analyses that included both
BRCA1 and BRCA2 mutation carriers were stratified for
these genes. Analyses were adjusted for duration of OC
use (never, V5 years, >5 years, missing data) and number
of full-term pregnancies (nulliparous, 1, 2, z3). Analyses
were further complicated by the fact that more than
one mutation carrier could come from the same family
and could not therefore be considered independent.
Although Cox regression provides unbiased estimates
of the rate ratios, in this case, the SEs and confidence
intervals (CI) would be underestimated. To allow for the
fact that the data set included related individuals, a
robust variance approach was used to compute the
variance of the rate ratio estimates (28). This adjusts for
potential correlations between family members without
modeling the dependence explicitly. All analyses were
done using the STATA statistical software, version 8 for
Unix systems (Statacorp).
Results
The cohort characteristics are summarized in Table 1. In
the primary analysis, 1,641 BRCA1 and BRCA2 mutation
carriers were censored at breast cancer diagnosis, 253 at
ovarian cancer diagnosis, 51 at another cancer diagnosis,
186 at bilateral prophylactic oophorectomy, and the
remaining 1,188 at the age at interview. The majority of
the ovarian cancer cases were BRCA1 mutation carriers
(201 versus 52 BRCA2 mutation carriers). The mean age
at interview was lower for unaffected carriers in both
BRCA1 and BRCA2 mutation carriers, although the
differences in the mean age at censoring between affected
and unaffected were smaller.
The estimated hazard ratios (HR) for the risk of
developing ovarian cancer using weighted Cox regres-
sion analysis are shown in Table 2. Mutation carriers
with at least one full-term pregnancy did not have a
significantly different ovarian cancer risk compared with
nulliparous carriers. The HR estimates for the combined
and separate analyses of BRCA1 and BRCA2 mutation
carriers were all in excess of 1. However, BRCA1
mutation carriers with two, three, and four or more
full-term pregnancies were at a lower ovarian cancer risk
compared with BRCA1 mutation carriers with a single
full-term pregnancy (P = 0.03, P = 0.04, and P = 0.002,
respectively; P trend = 0.002). Furthermore, there was
evidence that nulliparous BRCA1 carriers were are at a
significantly decreased risk compared with carriers with
only one full-term pregnancy (HR, 0.45; 95% CI, 0.23-
0.88; P = 0.02). We repeated this analysis using a more
refined stratification by birth cohort (<1935, 1935-1939,
. . ., 1965-1969, z1970), to investigate whether this effect
was confounded by changes in parity by birth cohort,
but the estimates were virtually identical (HR for
nulliparous compared with women with a single
pregnancy, 0.42; 95% CI, 0.21-0.88; P = 0.02). The
estimated HRs by parity in BRCA1 and BRCA2 carriers
were very similar. However, none of the estimates were
significant in BRCA2 carriers due to the small number of
events. There was no significant evidence that the age at
first full-term pregnancy was associated with ovarian
cancer risk.
For parous mutation carriers, there was some indica-
tion that breast-feeding may be protective for ovarian
cancer but the results were not significant (BRCA1 : HR,
0.90; 95% CI, 0.61-1.32; BRCA2 : HR, 0.72; 95% CI, 0.27-
1.91). There was no apparent trend in risk with
increasing duration of breast-feeding. Similarly, the HR
estimates decreased with increasing age at menarche,
but none of the associations were statistically significant
(P trend = 0.20 and 0.82 for BRCA1 and BRCA2 ,
respectively).
Mutation carriers who had ever used OCs were at a
significantly reduced risk of developing ovarian cancer
(HR, 0.55; 95% CI, 0.40-0.76; P = 0.0003 in BRCA1 and
BRCA2 combined). The effect was restricted to BRCA1
mutation carriers only (HR, 0.52; 95% CI, 0.37-0.73;
P = 0.0002). Increasing duration of OC use was also
associated with a reduced risk of ovarian cancer with
HR estimates of 0.60 (95% CI, 0.35-1.03), 0.41 (95% CI,
0.19-0.87), 0.35 (95% CI, 0.22-0.55) for durations of use
1 to 3 years, 3 to 5 years, and more than 5 years,
respectively, for BRCA1 and BRCA2 mutation carriers
combined (P trend = 0.0003). The effect was mainly
driven by BRCA1 mutation carriers (P trend = 0.0004),
but the number of BRCA2 mutation carriers in individual
categories was too small to draw reliable conclusions.
There was no evidence that the age at first OC use was
associated with ovarian cancer risk. There was some
indication that BRCA1 carriers who started taking OCs
after 1975 were at higher risk, but the difference in risk
by year of first use was not statistically significant and
no such effect was apparent in BRCA2 carriers. The
protective effect of OCs for BRCA1 mutation carriers
seemed to be greater for more recent users. The HR for
ovarian cancer for BRCA1 mutation carriers who were
current users or used OCs within the past 10 years (with
respect to the age at censoring) was estimated to be 0.28
(95% CI, 0.17-0.48) compared with 0.80 (95% CI, 0.55-
1.18) for BRCA1 mutation carriers who last used OCs
more than 10 years ago (PHet = 0.0002). A similar pattern
was observed for BRCA2 (PHet = 0.04).
Tubal ligation was associated with a reduced risk of
ovarian cancer for BRCA1 and BRCA2 mutation carriers
combined (HR, 0.43; 95% CI, 0.24-0.75; P = 0.003) and for
BRCA1 carriers alone (HR, 0.42; 95% CI, 0.22-0.80). The
HR for BRCA2 mutation carriers was very similar to that
in BRCA1 carriers but it was not significant. There was
no significant evidence that the protective effect of tubal
Ovarian Cancer Risk Factors in BRCA1/2 Carriers
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ligation varies with the age at which the surgery took
place.
Duration of HRT use was not associated with ovarian
cancer risk for BRCA1 or BRCA2 mutation carriers
(P = 0.70 and 0.90, respectively). Similarly, there was
no association between past hysterectomy and the risk of
ovarian cancer in BRCA1 or BRCA2 mutation carriers
(HR, 0.68; 95% CI, 0.22-2.12 and HR, 0.35; 95% CI, 0.08-
1.58, respectively), although the number of women who
had had a previous hysterectomy was small.
We repeated the above analyses, including follow-up
after a first breast cancer diagnosis. In this analysis,
mutation carriers who were previously censored at a
breast cancer diagnosis were followed until the first of
the subsequent events occurred: contralateral breast
cancer diagnosis (392), bilateral prophylactic oophorec-
tomy (210), ovarian cancer diagnosis (64), other cancer
diagnosis (53), or at interview (922). This analysis thus
added an additional 64 events and 9,729 person-years
of follow-up. The results were virtually identical to the
analysis in which BRCA1 and BRCA2 mutation carriers
were censored at the first breast cancer diagnosis. In
particular, the observed pattern of risk seen with the
number of full-term pregnancies remained the same, a
single full-term pregnancy was associated with an
increased risk of ovarian cancer compared with nullip-
arous carriers (HR, 2.35; 95% CI, 1.25-4.41; P = 0.008 in
BRCA1 mutation carriers), but increasing number of
pregnancies were associated with a reduced ovarian
cancer risk (HR, 0.61; 95% CI, 0.41-0.92; HR, 0.59; 95% CI,
0.37-0.94; HR, 0.31; 95% CI, 0.16-0.61, for two, three, and
four or more pregnancies, respectively, compared with
BRCA1 carriers with a single pregnancy; P trend = 0.002).
Similarly, increasing duration of OC use was also
associated with a reduced risk of ovarian cancer (HR,
0.92; 95% CI, 0.60-1.41; HR, 0.48; 95% CI, 0.27-0.83; HR,
0.36; 95% CI, 0.16-0.77; HR, 0.37; 95% CI, 0.24-0.56 for
durations of 0-1, >1-3, >3-5, and >5 years, respectively).
The estimated HRs were also similar for the other risk
factors, but the significances of the associations in BRCA1
carriers were slightly stronger. None of the HR estimates
were significantly different from 1.0 in BRCA2 carriers, in
line with the primary analysis.
Discussion
We used data on 3,319 BRCA1 and BRCA2 mutation
carriers from the IBCCS study to investigate the effect of
reproductive and hormonal factors on the risk of ovarian
cancer risk in mutation carriers. We found evidence that
increasing number of full-term pregnancies among
parous women, OC use, and tubal ligation are associated
with a reduced risk of ovarian cancer for BRCA1
mutation carriers. The number of ovarian cancer cases
in BRCA2 mutation carriers was too small to draw
definitive conclusions for the associations in this group of
carriers. We found no significant evidence that breast-
feeding, age at menarche, HRT, or hysterectomy are
associated with ovarian cancer risk in BRCA1 or BRCA2
mutation carriers. Our data comes from a large series of
BRCA1 and BRCA2 mutation carriers that are largely
independent from those already published. Some over-
lap may exist with the study of McLaughlin et al. (16),
but the exact number of carriers that are common
between the two studies is difficult to establish. Based
on the reported country of residence of mutation carriers
in that report and in the IBCCS cohort, the maximum
potential overlap between our study and the McLaughlin
et al. study would be 297 carriers, or 8.9% of our data set,
but the true overlap is likely to be much smaller.
The data were analyzed within a Cox proportional
hazards framework, using differential weighting of
carriers censored at a breast cancer diagnosis, an ovarian
cancer diagnosis and those who were unaffected, to
reflect the nonrandom sampling of mutation carriers with
respect to their disease phenotypes which includes both
the cancer site and age at diagnosis or censoring (for
unaffected). The main advantages of this approach over
other approaches (e.g., a matched case-control design) are
that testing bias is optimally adjusted for and all BRCA1
and BRCA2 mutation carriers in the IBCCS cohort were
used in the analysis, and therefore, the power of the study
was not compromised (27). BRCA1 and BRCA2 mutation
carriers with a first breast cancer diagnosis were assumed
to be unaffected in our analysis. A potential bias in the
estimated HRs for ovarian cancer could arise if the risk
factor under investigation is also associated with breast
cancer risk in mutation carriers (which in this case, many
are). However, in our analyses, mutation carriers cen-
sored at breast cancer diagnosis were assigned breast
cancer–specific weights which were lower than the
weights assigned to mutation carriers censored at the
age at interview (reflecting the oversampling of affected
carriers). Therefore, our weighting scheme would correct
for such a bias if the associations are in the same direction
for breast and ovarian cancer. In addition, we carried out
further analyses which included the follow-up time after
the first breast cancer diagnosis, treating the first breast
cancer diagnosis as a time-dependent covariate, and the
results were virtually identical to those in the primary
analyses.
This is one of the largest studies of risk factors for
ovarian cancer in BRCA1 and BRCA2 carriers to date.
Nevertheless, the number of carriers diagnosed with
ovarian cancer in our study is still relatively small,
particularly among BRCA2 mutation carriers. Therefore,
our study is underpowered to detect the effect of risk
factors which confer a small increase or decrease in
ovarian cancer risk. The analysis which included the
follow-up time after the first breast cancer diagnosis
increased power somewhat, but no further significant
associations were detected. Larger studies of BRCA2
mutation carriers will be necessary to address the
associations between these factors and ovarian cancer
risk with certainty.
Both prevalent and incident ovarian cancer cases were
considered in our analysis. The mean time between an
ovarian cancer diagnosis and the age at interview in our
study was 6.7 years. The inclusion of prevalent cases
could potentially bias our estimates if the risk factors
under investigation were also associated with survival
after an ovarian cancer diagnosis. A study by McLaugh-
lin et al., which investigated the effect of reproductive
and hormonal factors on ovarian cancer risk in BRCA1
and BRCA2 mutation carriers, found that their results
were similar between analyses which included both
prevalent and incident cases and analyses which were
restricted to incident ovarian cancer cases (16). Further-
more, studies in the general population have not found
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an association between reproductive or hormonal factors
and survival except from breast-feeding (29). Women
who had ever breast fed were found to have a better
prognosis in the general population. If the same is true
for carriers, this might have attenuated a real protective
effect. These considerations suggest that our remaining
results are unlikely to have been influenced by the
inclusion of prevalent ovarian cancer cases.
One potential source of bias in our analyses was that
61.7% of the mutation carriers censored upon diagnosis
of ovarian cancer were born before the year 1950,
whereas this was true for only 29.2% of the remaining
women. In our main analysis, birth cohort was
categorized in 10-year intervals, and we suspected that
this categorization might be too broad to fully adjust for
the cohort effect. We therefore repeated the analysis
using 5-year birth cohort categories, but the results were
similar.
We found a curious pattern of risk associated with
parity. Among parous women, we saw a clear reduction
in risk by number of full-term pregnancies in both
BRCA1 and BRCA2 carriers. These results are in line with
studies of ovarian cancer in the general population in
which parity is associated with a reduced risk of ovarian
cancer (10). However, nulliparous women were at a
lower risk of ovarian cancer than women with one
pregnancy, so that overall nulliparity was associated
with a slight, although nonsignificant reduction in risk.
This latter effect is not consistent with the effects seen in
the general population. Previous studies in BRCA1
mutation carriers alone or BRCA1 and BRCA2 mutation
carriers combined have, in general, reported a protective
effect of parity for ovarian cancer, but the effect was not
always significant (14, 15, 17). In the largest study to
date, McLaughlin et al. (16) reported a significant 44%
reduction in the risk of ovarian cancer risk in parous
BRCA1 mutation carriers, but parity was associated with
an increased risk of ovarian cancer in BRCA2 mutation
carriers. The 95% CI of our HR estimate for BRCA1
mutation carriers does not include the estimate of
McLaughlin et al. (16). Our estimated effect among
BRCA2 mutation carriers is consistent with their OR
estimate of 2.74 but our analyses were based on a small
number of BRCA2 mutation carriers. However, we saw
no evidence to suggest a differential effect of parity in
BRCA1 and BRCA2 carriers.
Given the results in the general population and the
apparently clear association with the number of children,
the increased risk in nulliparous women seems likely to
be an artifact. This could arise if there was a difference in
the HR by attained age as observed in the case of breast
cancer (23). In our data set, the ovarian cancer HR for
parous BRCA1 mutation carriers who were less than
45 years of age is estimated to be 2.47 (95% CI, 0.97-6.30),
but the HR for those who were 45 years or older was 0.82
(95% CI, 0.36-1.89). However, the difference in the HR
between the two groups is not significant (P = 0.09) and
larger studies will be necessary to investigate this
possibility. Another explanation could be selection bias,
whereby a woman’s decision to test for BRCA1 and
BRCA2 mutations depends both on the diagnosis
(ovarian/breast cancer or unaffected) and on the number
of children she has. In particular, the result we observed
could be generated if women with ovarian cancer
preferentially come forward for testing if they have
children.
One previous study found that breast-feeding protects
against ovarian cancer in BRCA1 mutation carriers (16),
but others have not found this association (15, 14).
Although we found no significant effect for breast-
feeding among BRCA1 mutation carriers, our HR
estimate is <1.0 and has a CI that includes the
McLaughlin et al. estimate (16). The estimates for BRCA2
mutation carriers were identical in the two studies (0.72),
but were both nonsignificant.
We found no significant evidence that age at menarche
was associated with ovarian cancer risk, but the
estimates suggest that risk may decrease with increasing
age at menarche in both BRCA1 and BRCA2 mutation
carriers. Two previously published studies in BRCA1
mutation carriers also found no association between age
at menarche and ovarian cancer risk (14, 15).
We found that OC use was associated with a reduction
in ovarian cancer risk, and that increasing duration of use
was inversely related to ovarian cancer risk in BRCA1
mutation carriers. These findings are in line with the
results in the general population (9, 10) and of several
other studies in mutation carriers (14-16, 18, 20), although
there have been studies which found no effect (17). In the
largest study, McLaughlin et al. (16) found a 61%
reduction in ovarian cancer risk in BRCA1 mutation
carriers, slightly higher, but consistent with our estimate
(48%). Duration of more than 5 years of OC use was
associated with similar risk reduction in both studies
(63% versus 66% risk reduction in our study). Therefore,
our results provide an independent confirmation of the
effect of OCs on ovarian cancer risk for BRCA1 mutation
carriers. We found no such association for BRCA2
mutation carriers, but the sample size was small and
our CI does not exclude the estimate of McLaughlin et al.
(16) or the estimate in BRCA1 carriers in our study. In
addition, we found that the protective effect was greater
in more recent users of OC, although the protective effect
persisted even after 10 years since last use in BRCA1
mutation carriers. This is in agreement with the recent
meta-analysis of studies in the general population (9).
There was no evidence that the risk of ovarian cancer
in BRCA1 and BRCA2 mutation carriers varied by HRT
use or by whether the carriers had had a hysterectomy.
Another small study of incident ovarian cancer cases in
BRCA1 mutation carriers found no effect with HRT use
(15). Rutter et al. (19) investigated the effect of a group
of gynecological surgeries including hysterectomy, uni-
lateral oophorectomy, and tubal ligation in BRCA1
and BRCA2 mutation carriers from Israel and found that
they were associated with a reduced risk of ovarian
cancer, but results were not presented for hysterectomy
alone. Although our estimated HR for the effect of
hysterectomy is consistent with estimates from studies in
the general population (10, 12, 19), larger studies will be
required to clarify the effect in mutation carriers.
Finally, we found that tubal ligation is associated with
a reduction in ovarian cancer risk in BRCA1 mutation
carriers. The estimated risk reduction in BRCA2 mutation
carriers (53%), although not significant, was similar to
that in BRCA1 mutation carriers (58%). One previous
study reported a significant association with tubal
ligation in BRCA1 mutation carriers (30), although the
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more recent re-analysis by the same group using
additional subjects found no significant effect (16). Our
estimated risk reduction is similar to that reported in the
general population.
Our results provide further confirmation that OC use
and tubal ligation are associated with ovarian cancer risk
in carriers, to a similar relative extent as in the general
population. The absolute difference associated with these
risk factors is, however, much greater in carriers. For
example, according to published BRCA1 ovarian cancer
risks (31), the average cumulative risk of developing the
disease by age 70 for an unaffected 40-year-old BRCA1
mutation carrier would be 32%. If we assume that our HR
estimate of 0.52 for ever OC use applies from the point of
first OC use for the remaining lifetime, then the
corresponding risk for a BRCA1 carrier who has never
used OC would be 41%, but for someone who had used
OC in the past, the corresponding risk would be 24%.
However, OC use has been associated with an increased
risk of breast cancer in the general population (21).
Estimates for the associations of OC use and the risk of
breast cancer risk for BRCA1 mutation carriers are
conflicting and therefore the precise effect of OC use on
breast cancer risk remains unresolved. Two studies
reported that OCs may increase the risk of breast cancer
in BRCA1 mutation carriers (22, 32), and one study
reported no association (33), whereas another study
reported that OC use may reduce the risk of breast cancer
for BRCA1 (34). Therefore, although OCs provide an
attractive approach to ovarian cancer risk reduction, their
use as chemoprevention for ovarian cancer risk needs to
take into account the precise effect on breast cancer risk.
Longer-term prospective studies will be needed to
establish definitively the balance between benefit and risk.
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Appendix A. Extending the Weighted Cohort
Approach To Account for Oversampling With
Respect To Both Breast And Ovarian Cancer
Our analyses are complicated by the fact that BRCA1 and
BRCA2 mutation carriers are not randomly sampled with
respect to their disease status. Many carriers are sampled
through families seen in genetic clinics. The first tested
individual in a family is usually someone diagnosed with
cancer at a relatively young age. Such study designs
therefore tend to lead to an oversampling of affected
individuals, and standard analytical methods such as
Cox regression might lead to estimates of the risk ratios
which are biased towards the null (27). The weighted
cohort approach for analyzing modifying risk factors
assigns relative weights to all study subjects to reflect the
probabilities with which they were sampled (27). We
have previously shown that this approach leads to
estimates which are close to unbiased at the expense of
some loss in power (27). Here, we extend this approach
to reflect the fact that BRCA1 and BRCA2 mutation
carriers are oversampled with respect to both breast and
ovarian cancer. The aim is to correct the bias by
differential weighting of unaffected carriers, carriers
who are censored at breast cancer, and those censored
at ovarian cancer such that the breast and ovarian cancer
incidence rates implied by the weighted cohort agree
with incidence rates for BRCA1 and BRCA2 mutation
carriers derived from a separate study.
We assume that our study includes n subjects in which
individual i is followed up to age ti (either at breast
cancer, ovarian cancer, or censored as unaffected). Age is
divided into a number of intervals (in our case, at 5-year
intervals) such that in the k th age group, there are rk
breast cancer cases, dk ovarian cancer cases, and sk
censored individuals. We also assume that in age group
k , the breast cancer cases accumulate pk person years, the
ovarian cancer cases accumulate xk person years, and the
censored individuals accumulate qk person years. We
further assume that our study subjects are sampled from
a population with true breast cancer incidence rate lk in
age group k , and ovarian cancer incidence rate kk in age
group k . We then assign weights wk to the breast cancer
cases, zk to the ovarian cancer cases, and vk to the
censored subjects such that the observed incidence rates
agree with true incidence rates:
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where tk is the number of years in age interval k . The
numerators in these expressions represent the weighted
number of cases occurring in the interval and the
denominators the total weighted person years accumu-
lated in age group k by all the individuals at risk. As in
Antoniou et al. (27), to obtain a unique solution, we
impose further constraints such that the average contri-
bution of breast and ovarian cancer cases and censored
individuals in each age group is equal to 1, that is,
wkrk þ vksk þ zkdk
rk þ sk þ dk
Although other constraints are possible, this provides
a solution in which the variances of the estimates are not
seriously compromised, as compared with the unweight-
ed estimates. It is then possible to iteratively solve the
three sets of equations above for wk, zk , and vk , for each
age group k .
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